RNA-Seq of Human Neurons Derived from iPS Cells Reveals Candidate Long Non-Coding RNAs Involved in Neurogenesis and Neuropsychiatric Disorders

doi:10.1371/journal.pone.0023356

PLoS One. 2011; 6(9): e23356.

Published online 2011 September 7. doi: 10.1371/journal.pone.0023356

PMCID: PMC3168439

Copyright Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

RNA-Seq of Human Neurons Derived from iPS Cells Reveals Candidate Long Non-Coding RNAs Involved in Neurogenesis and Neuropsychiatric Disorders

Mingyan Lin,¹ Erika Pedrosa,² Abhishek Shah,² Anastasia Hrabovsky,² Shahina Maqbool,¹ Deyou Zheng,^1,^3,⁴ and Herbert M. Lachman^2,⁵^*

¹Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, United States of America

²Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York, United States of America

³Dominick Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, United States of America

⁴Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, United States of America

⁵Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, United States of America

Takeo Yoshikawa, Editor

Rikagaku Kenkyūsho Brain Science Institute, Japan

* E-mail: Herb.Lachman/at/einstein.yu.edu

Conceived and designed the experiments: HL. Performed the experiments: EP AH SM AS. Analyzed the data: DZ ML. Wrote the paper: HL.

Received June 17, 2011; Accepted July 12, 2011.

This article has been cited by other articles in PMC.

Abstract

Genome-wide expression analysis using next generation sequencing (RNA-Seq) provides an opportunity for in-depth molecular profiling of fundamental biological processes, such as cellular differentiation and malignant transformation. Differentiating human neurons derived from induced pluripotent stem cells (iPSCs) provide an ideal system for RNA-Seq since defective neurogenesis caused by abnormalities in transcription factors, DNA methylation, and chromatin modifiers lie at the heart of some neuropsychiatric disorders. As a preliminary step towards applying next generation sequencing using neurons derived from patient-specific iPSCs, we have carried out an RNA-Seq analysis on control human neurons. Dramatic changes in the expression of coding genes, long non-coding RNAs (lncRNAs), pseudogenes, and splice isoforms were seen during the transition from pluripotent stem cells to early differentiating neurons. A number of genes that undergo radical changes in expression during this transition include candidates for schizophrenia (SZ), bipolar disorder (BD) and autism spectrum disorders (ASD) that function as transcription factors and chromatin modifiers, such as POU3F2 and ZNF804A, and genes coding for cell adhesion proteins implicated in these conditions including NRXN1 and NLGN1. In addition, a number of novel lncRNAs were found to undergo dramatic changes in expression, one of which is HOTAIRM1, a regulator of several HOXA genes during myelopoiesis. The increase we observed in differentiating neurons suggests a role in neurogenesis as well. Finally, several lncRNAs that map near SNPs associated with SZ in genome wide association studies also increase during neuronal differentiation, suggesting that these novel transcripts may be abnormally regulated in a subgroup of patients.

Introduction

Research on the biological basis of SZ and other neuropsychiatric disorders has been hampered by the inaccessibility of the human brain. However, the discovery of iPSC technology has the potential to address this problem by providing investigators with patient-specific neurons that can be used for disease modeling. In the past few years, investigators have taken advantage of this opportunity to establish iPSC lines in a variety of neuropsychiatric disorders including Rett Syndrome, Parkinson Disease, Amyotrophic Lateral Sclerosis, Familial Dysautonomia, and most recently, SZ [1]–[12]. In the study reported by Brennand et al. neurons derived from SZ-specific iPSCs showed diminished neuronal connectivity, reduced PSD95-protein levels and altered expression of WNT signaling pathways [1]. Similarly, we have also been developing iPSC lines from patients with SZ, a data set that includes patients with 22q11.2 deletions (in press).

In addition to their utility for disease modeling in neuropsychiatric problems, iPSCs can also be used to study early differentiating human neurons in vitro to gain insight into neurogenesis, which is particularly relevant to both SZ and ASD considering that both appear to have a neurodevelopmental basis [13]–[16].

With these aspects of disease pathogenesis in mind, we have analyzed the transcriptome of human neurons derived from iPSCs using RNA-Seq, a method that provides increased sensitivity with the capacity to detect low-copy transcripts, novel transcripts, lncRNAs, and splice isoforms [17]–[20]. The key role played by cell type-specific splicing in neuronal differentiation, particularly in genes coding for cell adhesion proteins, and the growing recognition that lncRNAs play a role neurogenesis lend further support for the value of deep sequencing transcriptome analysis [21]–[23].

Finally, a global, unbiased transcriptome analysis could help determine the biological significance of SNP markers associated with neuropsychiatric disorders identified in GWAS carried out in SZ, ASD, BD, many of which map to intergenic regions or deep within large introns where important regulatory lncRNAs may be found [24]–[26].

Our findings show that early differentiating neurons undergo an extraordinary array of quantitative changes in gene expression and in splice isoform generation, similar to that reported in differentiating human neurons derived from human embryonic stem cells (hESCs) [27]. In addition, we describe dramatic changes in expression of lncRNA genes during differentiation, one of which is HOTAIRM1, a cis-acting regulator of the HOXA cluster during myelopoiesis [28]. Contrary to previous reports suggesting that HOTAIRM1 is not expressed in brain, a 54.6-fold increase in transcripts was detected in differentiating neurons, suggesting a novel role in neural differentiation. In addition, some GWAS SNPs found in SZ, BD and ASD mapped to lncRNA genes that are expressed in differentiating neurons, suggesting a role for these novel regulators in a subgroup of patients.

Methods

This study was approved by the Internal Review Board of the Albert Einstein College of Medicine (protocol number 1996-013). Informed consent was obtained and the data were analyzed anonymously in accordance with the Declaration of Helsinki.

iPSCs and neural differentiation

Details regarding the generation of iPSCs and the neuronal differentiation protocol used are described in Text S1.

RNA-Seq

Total RNA was isolated from cells using the miRNeasy Kit (Qiagen) according to the manufacturer's protocol. An additional DNase1 digestion step was performed to ensure that the samples were not contaminated with genomic DNA. RNA purity was assessed using the ND-1000 Nanodrop. Each RNA sample had an A260 [ratio]

A280 ratio above 1.8 and A260 [ratio]

A230 ratio above 2.2. Briefly, total RNA (25 ng) was converted to cDNA using the NuGEN Ovation RNA-Seq System according to the manufacturer's protocol (NuGEN, San Carlos, CA, USA). The protocol employs a single primer isothermal amplification (SPIA) method to amplify RNA target into double stranded cDNA under standardized conditions that markedly deplete rRNA without preselecting mRNA. cDNA was then used for Illumina sequencing library preparation using Encore NGS Library System I. NuGEN-amplified double-stranded cDNA was fragmented into ~300 base pair (bp) using a Covaris-S2 system. DNA fragments (200 ng) were then end-repaired to generate blunt ends with 5′ phosphatase and 3′ hydroxyls and adapters were ligated for paired end sequencing on Illumina HiSeq 2000. The purified cDNA library products were evaluated using the Agilent bioanalyzer and diluted to 10 nM for cluster generation in situ on the HiSeq paired-end flow cell using the CBot automated cluster generation system followed by massively-parallel sequencing (2×100 bp) on HiSeq 2000. We obtained 104-bp mate-paired reads from DNA fragments of average length of 250-bp (standard deviation for the distribution of inner distances between mate pairs is approximately 50 bp). iPSC and neuron RNA-Seq reads were separately aligned to the human genome (GRCh37/hg19) using the software TopHat (version 1.1.4) [29].

Splice junctions were automatically determined by TopHat, with the provided guidance of annotated gene models (GTF file) obtained mainly from Ensembl (http://www.ensembl.org). In our analysis, all three splice sites, “GT-AG”, “GC-AG” and “AT-AC” were considered. All splicing junctions supported by at least one high-quality mapped read were kept. The option for searching novel splice variants in Tophat was left on. The resulting alignment data from Tophat were then fed to an assembler Cufflinks (version 0.9.3) to assemble aligned RNA-Seq reads into transcripts [29]. Annotated transcripts were obtained from the UCSC genome browser (http://genome.ucsc.edu) and the Ensembl database; the category of transcripts was described at http://vega.sanger.ac.uk/info/about/gene_and_transcript_types.html. The number of transcripts in each category is listed in Table 1. Transcript abundances were measured in Fragments Per Kilobase of exon per Million fragments mapped (FPKM), which originated from the idea of RPKM (Reads per Kilobase per Million) [19]. To address the common issue in the assembly that a read may align to multiple isoforms of the same gene or multiple transcripts within the same genetic locus, maximum likelihood estimation was performed by Cufflinks based on a numerical optimization algorithm for calculating FPKM. Finally, the program Cuffdiff was used to define differential expression [29]. Instead of using transcript abundances computed separately by Cufflinks for each condition, Cuffdiff took alignment data from both iPSC and day 10 neurons, together with a list of human genome annotations (the same GTF file as used above, including both coding and non-coding transcripts) to infer expression differences at the level of transcript isoforms or primary transcripts or genes. Since we only had one replicate, the variance of FPKM was directly estimated from read counts using Poisson distribution, as described in detail at the Cufflinks website (http://cufflinks.cbcb.umd.edu/howitworks.html#hdif). In brief, the counts of reads that mapped to all nucleotides within a gene/transcript were assumed to follow Poisson distribution and then their mean was used as the variance. Student's t-test was then used to find significantly differentially expressed transcripts, with the test statistic derived from the log ratio of FPKM values in our two samples (see Cufflinks website for further details). To overcome the known bias in data normalization arising from a small number of highly expressed genes, we normalized our iPSC and neuronal data with total number of fragments mapped to the upper quartile of high expressed genes/transcripts rather than total mapped fragments [30].

Table 1

RNA-Seq Summary.

Validation by reverse transcriptase PCR (RT-PCR) and quantitative real time PCR (qPCR)

Selected genes and splice variants were validated by RT-PCR and qPCR using standard protocols that are described in detail in the Text S1. The primers used in these analyses are shown Table S1.

Results

Complementary DNA was generated using RNA extracted from iPSCs and a 10 day cluster of neurons. Samples were amplified prior to paired-end deep sequencing as described in the methods section. More than 1×10⁸ pairs of reads were obtained for each sample, of which 74.3% and 82.3% had at least one end mapped to the reference genome (see legend Table 1 for details). The expression of 9008 genes was significantly altered as the iPSCs differentiated into neurons (q-value<0.05) (Table 1) (for a complete list of genes that showed significant changes in expression see Table S2). Of these, 5953 genes decreased in expression, while 3055 genes increased. Although the majority of these significantly altered genes were protein coding (4060 and 1808, respectively), approximately one-third were non-coding, findings similar to previous reports showing widespread expression in both coding and non-coding regions [31]–[34].

Consistent with the differentiation of iPSCs into neurons, substantial 10 to >1,000-fold decreases were detected in the expression of genes associated with pluripotency such as OCT4 (POU5F1), JARID2, NANOG, and LIN28A, with a concomitant increase in expression of transcription factors associated with neural differentiation, including POU3F2, MYT1L, NEUROD1, and MEF2C (Table S3). MYT1L, POU3F2, along with ASCL1, are transcription factors capable of converting fibroblasts directly into neurons [35].

The most highly expressed genes in iPSCs were TPT1, PTMA, NCL, NASP, and HSP90AB1. TPT1 (tumor protein, translationally-controlled 1) is involved in maintaining embryonic stem cell phenotype and interacts with OCT4 and NCL (nucleolin), a nucleolar phosphoprotein involved in ribosomal maturation [36]–[38]. PTMA (prothymosin, alpha isoform 2) is over-expressed in a number of different cancers and interacts with histone acetyltransferases. NASP codes for nuclear autoantigenic sperm protein isoform 2 a histone H1 binding protein expressed in all dividing cells, inhibits proliferation and induces apoptosis in prostate cancer PC-3 cells, and is one of the hub genes involved in maintaining stem cell fate [39].

Among the most highly expressed genes in neurons were TPT1, TUBA1B, HNRNPA2B1, C5orf13, RPS6, NCL, CANX, and RPL35A. C5orf13 is neuronal protein 3.1 isoform A and is expressed in fetal and adult brains. Ribosomal protein S6 (RPS6) is phosphorylated in response to an array of growth factors and mitogens, a process that may be disrupted in Rett Syndrome [40]. However, among the top 25 genes that are the most highly expressed in neurons, all show higher levels of expression in iPSCs.

More interesting are the genes that show the most dramatic shifts in gene expression – both increases and decreases – during the transition from iPSCs to neurons. Among the transcripts that decreased radically were SCGB3A2, POU5F1, DMKN, C14orf115, PRDM14, HLA-DPB2, POU5F1P1, TRIML2, MT1F, MT1X, CYP2S1, and IDO1. SCGB3A2 (secretoglobin, family 3A, member 2 precursor) maps to 5q32 and is a downstream target of the homeodomain transcription factor NKX2-1, which is critical for the development of lung, thyroid and ventral forebrain [41]. DMKN (dermokine isoform 1 precursor) is primarily expressed in skin and its expression in iPSCs is probably due to residual expression of fibroblast specific genes. PRDM14 is a member of the PR domain and zinc finger proteins involved in transcriptional regulation. It is expressed in pluripotent stem cells and is involved in mouse embryonic stem cell (mESC) self-renewal, overlapping with Nanog and Oct4 in its binding domain [42]. In addition, PRDM14 regulates the expression of OCT4 and is part of the network of genes involved in reprogramming human fibroblasts [43]. Finally, POU5F1P1 may be a processed pseudogene or codes for a protein that binds to the nucleus that is believed to be involved in malignant transformation [44]–[46].

Considering the high level of expression in iPSCs and the rapid and dramatic decline that occurs during differentiation, some of these genes could be candidates for maintaining pluripotency or modulating cell type or region specific neural differentiation.

Another gene that showed one of the most significant fold-decreases during neuronal differentiation is FZD5 (frizzled 5 precursor), a receptor for WNT5A, which is particularly interesting in the context of neuropsychiatric disorders because signaling through canonical WNT-mediated signal transduction appears to be involved in SZ and BD in subgroups of patients [1], [47]–[50]. Down regulation of FZD5 mediated signal transduction, similar to that described in differentiating hESCs, is consistent with a role in maintaining pluripotency [27].

L1TD1 codes for LINE-1 type transposase domain containing 1. This gene appears to be a partner in the Oct4 interactome based on a protein affinity-based assay [51]. There is some evidence that L1 retrotransposition occurring selectively in neuronal progenitor cells could be a factor in brain development [52], [53].

Among the genes that showed the largest fold increase in expression during the transition from iPSCs to neurons was CARTPT (also known as CART), which codes for a neuropeptide involved in regulating food intake, reward and endocrine functions [54]. It is expressed in the hypothalamus and throughout the mesocorticolimbic dopamine reward system (nucleus accumbens shell, amygdala complex, extended amygdala and orbitofrontal cortex [55], [56].

Others include STMN4 (stathmin-like 4), a member of the stathmin family that encode phosphoproteins involved in regulating the microtubule filament system in the brain, the AMPA2 receptor gene GRIA2, ZIC4, a zinc finger transcription factor expressed in the dorsal midline of the forebrain and in the boundary between the diencephalon and telencephalon, SCN3A, which codes for a sodium channel, voltage-gated, type III, alpha subunit and has been implicated in seizure disorders and neuropsychiatric problems, EPHA3, an ephrin receptor, the potassium channel encoding KCNK2, DCC (deleted in colorectal cancer) which codes for a receptor for the axon guidance protein netrin-1, and SYT4 (synaptotagmin 4), a negative regulator of oxytocin release [57]–[59].

Several members from each of the four HOX families are among the most differentially expressed genes. HOX genes are involved in brain patterning in the development of forebrain, midbrain and hindbrain, and abnormal expression has been implicated in mental retardation, subtypes of ASD, and epilepsy [60]–[62].

Finally, previous work from our lab shows that the differentiation method we use results primarily in the development of glutamatergic neurons. This is reflected in the gene expression profile here, which shows that the glutamate transporter, SLC17A6, (VGLUT2) is among the most highly differentially expressed genes (Tables S2 and S3). By contrast, SLC32A1 (VGAT, GABA vesicular transporter), SLC6A20 (NET, norepinephrine transporter), SLC6A4 (SERT, serotonin transporter), and SLC18A1 and SLC18A2 (VMAT1 and VMAT2A; vesicular monoamine transporters) were not expressed. The dopamine transporter gene, SLC6A3, (DAT1) was expressed, but at 1/50^th the level of SLC17A6 (Table S2).

The list of significantly altered genes was subjected to bioinformatics analysis using Gene Ontology (GO) to determine functional enrichment [63]. This showed changes in gene expression that were consistent with the conversion of pluripotent stem cells into terminally differentiated neurons (Table 2). In addition, there was high correlation (R

0.64) between the results obtained with pre-amplified RNA using RNA-Seq and total RNA using standard microarray expression profiling (Fig. 1). The findings show that faithful amplification of RNA can be achieved, which is important for studying gene expression profiles in small numbers of neurons.

Table 2

Gene Ontology (GO) terms for differentially expressed genes.

Figure 1

Comparison of fold-changes (log₂-transformed) of gene expression between iPSCs and day 10 neurons as measured by RNA-Seq (x-axis) and Affymetrix microarray (y-axis).

lcnRNAs and lincRNAs

A substantial fraction of transcripts in mammalian genomes do not code for proteins. These include lncRNAs and lincRNAs (long intergenic non-coding RNAs), which are arbitrarily defined as greater than 200 bases in length, to distinguish them from functional small non-coding transcripts, such as microRNAs (miRNAs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs).

LncRNAs (also known as processed transcripts) by definition are found within protein coding genes, overlapping with promoters, exons or introns in either sense or antisense orientations. LincRNAs, on the other hand, are found in intergenic regions. Two well-known lncRNAs are Xist, which initiates X-chromosome inactivation in females and HOTAIR, which is embedded within the HOXC locus, but has a trans-repressive effect on HOXD expression [64]–[66]. Other lncRNAs involved in regulating HOX gene expression are HOTAIRM1 and HOTTIP [28], [67]. There is increasing evidence that lncRNAs are involved in stem cell pluripotency and brain development [22], [68]–[70]. Khalil et al showed that ~20% of lincRNA bind to polycomb repressive complex 2 (PRC2), suggesting that many regulate gene expression at the chromatin level [71].

As shown in Table 1, 1622 non-coding genes (including lncRNAs and lincRNAs) significantly increased or decreased in expression during the transition from iPSCs to neurons. The most abundantly expressed lincRNAs in iPSCs are MALAT1, SNHG6, SNORD87, CRNDE, and PVT1 (Table S4). MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) is also the most abundantly expressed lincRNA in differentiating neurons. It was initially identified in a screen for genes differentially expressed in metastatic non-small cell carcinoma [72]. MALAT1 appears to play a role in alternative splicing of pre-mRNAs since it localizes to nuclear speckles, dynamic structures that are essentially concentrations of splicing factors; it also recruits SR proteins, which participate in maturation of the splicosome [73]–[75]. MALAT1 is up-regulated in the brains of PCP-treated mice and plays a role in hippocampal synaptic function [76]. Although the difference in expression between iPSCs and day 10 neurons was statistically significant, mRNA levels increased only ~10%. However, to our surprise, there was a substantial difference in splice isoforms generated in iPSCs and neurons, including several that were specific to each (Fig. S1). The importance of this finding will require further study.

SNHG6/SNORD87 code for nucleolar RNAs, and PVT1 is non-coding RNA oncogene that regulates and is regulated by c-myc [77]. AL445670.1 is highly expressed in iPSCs and decreases 41-fold in neurons.

Among the lincRNAs that show the largest fold increases in neurons is CRNDE, a non-coding RNA of unknown function. CRNDE maps to 16q12.2, near the IRX5 gene, a member of the Iroquois homeobox family, which are involved in brain patterning and neurogenesis [78], [79]. The close proximity to IRX5 suggests that CRNDE may influence its expression.

Among the most highly expressed lncRNAs expressed in iPSCs are XIST, AC00967.5/METTL5, SNHG5/SNORD50, STMN1, and RP11-509I21.1,RP11-509I21.2,TDGF1 (Table S5). Embryonic stem cells from female mice are characterized by the absence of XIST expression resulting in activation of both X-chromosomes, one of which is subsequently randomly inactivated upon differentiation. However in human ESCs and iPSCs, XIST expression is heterogeneous, resulting in various patterns of X-chromosome inactivation; lines that do not express XIST show expression of genes from both X-chromosomes [64], [80]. The iPSC line used in this RNA-Seq analysis was from a female.

AC00967.5 maps to 2q31.1 and overlaps with the METTL5 (methyltransferase like 5) gene. It decreases 6-fold in neurons. RP11-509I21.1 and RP11-509I21.2 overlap with the OCT4 target TDGF1 (teratocarcinoma-derived growth factor 1; also known as CRIPTO) and is closely juxtaposed to the tumor suppressor gene LRRC2 (leucine rich repeat containing 2) [81], [82]. A >1,000-fold decrease in expression of transcripts in this region was found during the transition from iPSCs to neurons. TDGF1 is protein coding and is involved in NODAL signaling, which is a developmental program affecting midline, forebrain and left-right axis development [83]. Other lncRNAs that are highly expressed in iPSCs but decrease more than 50-fold in day 10 neurons include RP11-132A1.3, RP3-430A16.1, RP3-430A16.1, RP11-1144P22.1, RP11-509I21.1/RP11-509I21.2/TDGF1, RP11-498P14.2, RP11-366M4.3, AC005062.2/AC007001.3/MACC1. Some of these genes should be viewed as potential candidates for maintaining pluripotency.

Among the most interesting lncRNAs that show marked increases in expression in neurons is HOTAIRM1, which was suggested to be specific for myeloid cells [28]. However, we detected a 54.6-fold increase in transcripts in early differentiating neurons. Also, several other lncRNAs that map to HOX clusters showed dramatic increases in expression in day 10 neurons, including RP11-357H14.12 and AC036222.1, which map to the HOXB locus.

Other lncRNAs that show little or no expression in iPSCs, but significantly increase in early differentiating neurons, include CTA-211A9.5/MIAT, RP11-732M18.3, AC018730.1, AC011306.2, RP11-65D13.1, and CTB-12O2.1. AC018730.1 is only ~2kb upstream from POU3F3 (BRN-1), a member of the brain-expressed POU family of transcription factors that is transcribed in the opposite orientation. Whether or not they share a common promoter, as we previously described for closely aligned genes transcribed in opposite orientations, remains to be seen [84]. POU3F3 was not expressed in either the iPSC or neuron sample used in the RNA-Seq experiment.

Validation by RT-PCR and q-PCR

The expression of some of these non-coding elements was validated using RT-PCR and qPCR (Fig. 2). Considering the importance of HOX genes in neuronal migration and brain patterning, we focused primarily on those that map to the HOX loci since lncRNAs are known to be involved in their regulation. The RNA samples used in the validation were not amplified and were obtained from an independent set of neurons. AC018730.1 transcripts, for example, could not be detected in iPSCs, but were abundant in both day 14 and 27 neurons. In addition, it is expressed in both fetal and adult brain samples. Similarly, HOTAIRM1 RNA was detected in differentiating neurons but not iPSCs. However, in contrast to AC018730.1, expression in brain was restricted to the 9 week fetal sample. Expression of the other lncRNAs in the HOX gene loci - AC036222.1 and RP11-357H14.12 - was restricted to early differentiating neurons, and could not be detected in either fetal or adult brain. These findings suggest that the lncRNAs within the HOXA and HOXB loci are involved in early neurogenesis and brain development, and regulate expression of the HOX genes, and perhaps others, within specific developmental time frames.

Figure 2

Validation by RT-PCR and qPCR in unamplified RNAs.

We also validated the expression of CRNDE and MIAT by RT-PCR; lncRNAs that were highly expressed in both iPSCs and neurons. As seen in Fig. 2, there is a visible band in iPSCs that appears to increase in early differentiating neurons, similar to the RNA-Seq findings, which showed detectable transcripts in iPSCs that increased 3.7 and 3.6-fold in neurons (CRNDE and MIAT, respectively). Interestingly, CRNDE is expressed in fetal brain but transcripts could not be detected in adult brain samples, whereas MIAT is expressed in both.

qPCR was used to quantify the difference in expression in the un-amplified RNA samples. As seen in Fig. 2, a significant increase in expression was detected for both using qPCR that was in a range similar to that observed in the amplified RNA-Seq sample (CRNDE: 4.3-fold+/−2.1; MIAT: 8.7-fold+/−5.1; n

3 or 4, each qPCR determination carried out in triplicate, p

0.05 for both).

In addition to long non-coding RNAs, small non-coding RNAs were also found to be differentially expressed (Table 1). However, considering that the RNA amplification method we used does not accurately amplify small RNAs, the findings will not be discussed (a more definitive RNA-Seq analysis using a small RNA library prepared from an unamplified sample is currently being carried out).

Pseudogenes

Some pseudogenes appear to be biologically functional with proposed effects on regulating gene expression through a variety of means, including acting as a miRNA decoy and producing endogenous short interfering RNAs [46], [84]–[89]. The expression of 1371 pseudogenes changed significantly during the transition from iPSCs to neurons (Table 1).

The most highly expressed in both iPSCs and day 10 neurons were RP11-442A13.1 and RP11-320L13.2, which map to 9q33.1 and Xq13.1, respectively (Table S6). The pseudogenes that showed the most significant fold changes upon differentiation were TDGF3 (teratocarcinoma-derived growth factor 3, pseudogene; CRIPTO-3), which maps to Xq21.1, and RP11-492I2.1, which maps to an ELAVL4 intron. ELAVL4 transcripts increase significantly in our differentiating neurons and is induced in the brains of PCP treated rats [46], [76], [89], [90]. TDGF3 is expressed in malignant cells and decreases upon differentiation of human teratocellular carcinoma cells. Among the more interesting pseudogenes that decrease in neurons are POU5F1P4, which is derived from POU5F1, and TERF1P3 and TERF1P4. The parent gene (TERF1) codes for a component of the telomere nucleoprotein complex.

Splice Variants

Neuron specific splicing is regulated by several proteins, including NOVA1, a neuron specific RNA-binding protein, and the splicing inhibitor PTBP1 (polypyrimidine tract binding protein). PTBP1 expression decreases ~3-fold in day 10 neurons, while NOVA1 expression increases ~3-fold, consistent with their known effects on splicing in neuronal tissue. Our paired-end sequence reads allowed us to identify 143,586 splice junctions in iPSCs and 144,885 in day 10 neurons. Two examples are depicted in Fig. 3, which shows the changes in splice isoforms that occur in the SZ and ASD candidate gene, NRXN1. Expression across exons 19, 20 and 21 (asterisk in figure) is particularly interesting considering the importance of splice variants in this region, known as splice site 4, in determining glutamatergic vs GABAergic differentiation [91], [92]. We validated the apparent increase in expression across splice site 4 in this region by qPCR, which showed a 2.65-fold+/−0.79 increase in neurons (p<0.05).

Figure 3

Splice variants in NRXN1 (panel A) and NRG1 (panel B).

We also show splice isoforms in the SZ candidate gene NRG1. Overall, NRG1 transcripts increase ~10-fold in day 10 neurons and a rich array of splice isoforms that change during differentiation is observed. We validated the splice variant formed between exons 10 and 11 in the NRG1 protein isoform HRG-β2b using qPCR (denoted by asterisk). As seen in the figure, a 12.7+/−0.79 fold increase was detected in differentiating neurons (p<0.05).

These findings show that RNA-Seq using amplified RNA will faithfully identify splice isoforms, and that dramatic changes in the overall pattern of alternatively spliced transcripts in candidate genes for neuropsychiatric disorders is an early event in neurogenesis.

Relevance to neuropsychiatric disorders

As recently reported by Brennand et al., using neurons derived from patient-specific iPSCs is a valuable resource for gene expression profiling, which is the goal of our ongoing research as well [1]. However, important information related to SZ, ASD and BD pathogenesis can also be gleaned by studying molecular events occurring during human neurogenesis, even in the absence of patient vs control comparisons. For example, some of the most dramatic changes in gene expression in differentiating neurons in this study occur in genes involved in neuropsychiatric disorders that code for transcription factors and chromatin modifying enzymes. Subtle alterations in the expression of such genes during neurogenesis caused by genetic or environmental factors have the potential to induce long-lasting changes in neuronal and brain function. Among the SZ, BD, and ASD candidate transcription factors and chromatin modifiers that change dramatically in day 10 neurons are POU3F2, MYT1L, RFX4, ZNF804A, SMARCA2, and NPAS3, and the chromatin modifier JARID2, which regulates the polycomb repressive complex.

In addition, expression of a number of genes coding for proteins involved in cell-cell adhesion, synaptogenesis and trans-synaptic bridging that have been implicated in neuropsychiatric disorders increase in these early differentiating neurons. These include NRXN1, NRXN3, NLGN1, CTNNA2, NCAM1 (and its modulator ST8SIA2), CHL1, ELAVL4 and PCDH9 [93]–[116].

Another way RNA-Seq data can be useful in understanding the underlying molecular and genetic basis of neuropsychiatric disorders is to identify non-coding elements transcribed in differentiating neurons that map to regions of the genome implicated by GWAS or CNVs. Many SNPs associated with neuropsychiatric disorders map to large introns or intergenic regions that are far removed from coding elements or known regulatory domains. This makes it difficult to appreciate the biological relevance of the association signal; presumably associated SNPs are in LD with disease-causing, biologically active variants.

One such SNP is rs893703, which maps to chromosome 3 (position139,250,649) within an RBP1 (retinol binding protein) intron [117]. The SNP falls within a lncRNA that significantly increases in expression in differentiating neurons, RP11-319G6.1 (Table S7). RP11-319G6.1 is transcribed in the opposite orientation from RBP1, the latter of which decreases in differentiating neurons. RP11-319G6.1 expression was validated in a different sample of differentiating neurons and is also expressed in fetal and adult brain (not shown). Whether or not RP11-319G6 affects RBP1 expression or other genes, and is a factor in the positive association found between rs893703 and SZ remains to be determined. Retinoids, it should be pointed out, play a role in brain development and have been implicated in SZ, although the evidence is not strong [118], [119].

Similarly the lncRNA RP11-586K2.1, which maps to chromosome 8 (89,044,236–89,749,363) contains a SNP (rs12527359) found to be associated with SZ and BD in a GWAS meta-analysis [120]. RP11-586K2.1 increases ~3.5-fold in differentiating neurons. It should be viewed as a potential candidate gene for this GWAS signal since the nearest coding genes to rs12527359 are MMP16 (matrix metalloproteinase 16 isoform 1 and RIPK2 (receptor-interacting serine-threonine kinase 2), which are ~400 kb–1,000 kb away, respectively.

A list of coding and non-coding genes that are differentially expressed in the RNA-Seq analysis that contain SNPs mapped in several SZ, BD and ASD GWAS studies are shown in Table S7 [120]–[123].

Finally, our transcriptome analysis could be useful in narrowing down candidate genes in well-defined large copy variants that have been found in SZ and ASD; coding genes, lncRNAs and lincRNAs that significantly change in differentiating neurons should be viewed as feasible candidates underlying the psychiatric manifestations of the copy variant. The CNVs we evaluated in this manner were 22q11.2 del, 15q11.2 del, 15q13.3 del, 16p11.2 dup, 17q12 del, 1q21.1 del, and 3q29 del [98], [124]–[132].

A total of 51 coding and non-coding genes in these CNVs are differentially expressed during early neurogenesis (Table S7). Of these a few appear to be particularly interesting, including the nicotinic cholinergic receptor subunit gene CHRNA7, and QPRT, which codes for quinolinate phosphoribosyltransferase, an enzyme involved in metabolizing an endogenous exitotoxin (quinolinate) implicated in Alzheimer Disease and Huntington Disease. Interesting two genes coding for proteins involved in phosphatidylinositol glycan (GPI) anchor biosynthesis – PIGW (chr17) and PIGX (chr3) – map to CNVs that are differentially expressed during neurogenesis. GPI anchors are used in cells to attach hydrophilic proteins to cell membranes. The hydrophobicity WNT3A, a signal transduction pathway believed to be involved in subsets of patients with SZ and BD, is increased by GPI-like anchors [133].

Discussion

In this study we show that RNA from a limited sample can be reliably amplified preserving quantitative changes and splice isoform integrity. Several novel findings emerged, including the discovery that lncRNAs that map to the HOXA and HOXB gene loci are expressed early in neurogenesis, and that at least one, HOXAIRM1, is expressed in fetal brain. Considering the effect of HOTAIRM1 on HOXA gene expression and myelopoiesis, our findings suggest a similar role in neurogenesis as well, but that remains to be determined experimentally. Similarly, the two other lncRNAs that map to HOX gene loci, RP11-357H14.12 and AC036222.1, that increase in differentiating neurons are excellent candidates for regulating HOX gene expression in the developing brain. The HOX genes play a role in brain development by determining rhombomere segmental identity, regional neural identity and anterior posterior patterning during early embryogenesis [60], [62]. Most of the work on the role of HOX genes on brain development has been carried out in drosophila and mouse. Using neurons derived from iPSCs will provide an opportunity to study the regulation of these genes, their targets, and their apparent lncRNA regulators in human tissue, in vitro.

Although analyzing the transcriptome during neurogenesis in humans is inherently valuable on its own, we are primarily interested in its application to neuropsychiatric disorders. These goals are not mutually exclusive since some of these disorders - notably SZ and ASD - have developmental origins and a primary defect in neurogenesis has been suggested. The RNA-Seq findings highlight the possibility of studying transcriptional/chromatin regulators involved in these disorders, and their downstream targets. Furthermore, unbiased genome wide transcriptome analysis has directed our attention to GWAS SNP signals that map to lncRNAs that increase in expression in differentiating neurons. Mutations causing aberrant expression of these non-coding RNAs represent very feasible candidates for the biologically significant variants that presumably lie in LD with disease-associated SNPs. Functional assays, such as studying the effects of knocking down expression of these lncRNAs in differentiating neurons, and targeted DNA resequencing in patients with SZ are warranted.

Establishing a role for non-coding RNAs in a subset of patients with neuropsychiatric disorders would add a new dimension to the genetic heterogeneity already known to underlie SZ, ASD and BD and would be consistent with the growing literature showing that this class of genes play a role in brain development and neuronal function. Two non-coding RNAs have previously been suggested to be involved in SZ in subgroups of patients; DISC2 and AK127244 [84], [134], [135]. DISC2 is transcribed anti-sense to DISC1 exon 9 and maps a few kilobases 3′ the breakpoint of the 1 [ratio]

11 translocation that first targeted DISC1 as a candidate gene in SZ. Antisense expression across exon 9 could conceivably modulate alternative splicing involving this exon. However, this has not been established experimentally. AK127244 is immediately upstream of NRXN1, and we previously showed that the two genes share a common promoter [84]. While copy variation affecting NRXN1 is a fairly regular occurrence in patients with ASD and SZ, there have also been a few examples of copy loss in ASD in which only AK127244 is affected [136]. Although AK127244 and DISC2 transcripts were detected in the differentiating neurons we cultivated there was no significant change from that found in iPSCs.

Finally, RNA-Seq analysis revealed interesting aspects of alternative splicing that occur in differentiating neurons. Although this will be expanded in a subsequent paper, a few points are worth mentioning. For example, as shown in this paper, the generation of alternatively spliced isoforms in two candidate genes for SZ – NRG1 and NRXN1 – is a very early event in neurogenesis. This is consistent with the idea that abnormalities in neuronal migration and/or synaptogenesis, potential underlying factors in SZ, may begin as a gene expression programming problem in early differentiating neurons (either during fetal development and/or in the post-development brain).

In addition, novel splice isoforms were observed for the lncRNA MALAT1. MALAT1 codes for an 8.7 kb transcript, which generates a 7.5 kb RNA that localizes to nuclear speckles, and a 61 nucleotide tRNA-like cytoplasmic molecule of unknown function produced by 3′ processing [137]. Splice isoforms have not been observed in studies showing Northern blots for MALAT1. However, spliced ESTs in the MALAT1 gene locus that overlap with apparent spliced exons in our study have been isolated (UCSC Genome Browser, human EST track; Fig. S1). The different isoforms found in iPSCs and neurons suggest that MALAT1 produces alternative transcripts in a cell type specific manner that could potentially modulate its role in pre-mRNA processing. Such an effect would be consistent with the role of nuclear speckles, cell type specific nuclear organization, and nuclear architecture on the differentiation of neurons and other cell types [74], [138]–[140].

Supporting Information

Text S1

Supplementary materials and methods. Detailed description of iPSC development and neural differentiation.

(DOC)

Click here for additional data file.^{(54K, doc)}

Table S1

PCR primers and antibodies used in experiments.

(DOC)

Click here for additional data file.^{(36K, doc)}

Table S2

File contains all differentially expressed genes significant at q<0.05. Columns show Gene Symbols, Position (Hg19), FPKM in iPSCs (Day_0_FPKM) FPKM in early differentiating neurons (Day_10_FPKM, fold change in expression (ln fold-change), Uncorrected p-values, and Type of primary gene.

(XLS)

Click here for additional data file.^{(1.4M, xls)}

Table S3

Top coding genes: absolute expression in iPSCs, day 10 neurons, and fold increase and decrease.

(XLS)

Click here for additional data file.^{(40K, xls)}

Table S4

Top lincRNAs.

(XLS)

Click here for additional data file.^{(75K, xls)}

Table S5

Top lncRNAs.

(XLS)

Click here for additional data file.^{(35K, xls)}

Table S6

Top pseudogenes.

(XLS)

Click here for additional data file.^{(28K, xls)}

Table S7

Differentially expressed genes that map to genome wide association (GWAS) SNPs and copy number variants (CNVs) found in schizophrenia, bipolar disorder and autism spectrum disorders.

(XLS)

Click here for additional data file.^{(50K, xls)}

Figure S1

Splice isoforms found in MALAT1 transcripts. Top panel, iPSCs; bottom panel, day 10 neurons. Continuous reads from adjacent exons depicted by thin line. Exon sequences are thick blue lines. Direction of transcription from left to right. Spliced ESTs on UCSC Genome Browser shown in black.

(TIF)

Click here for additional data file.^{(586K, tif)}

Acknowledgments

The authors would like to thank the Epigenomic Shared Facility and Computational Genomics Core Facility for help in carrying out the RNA-Seq analysis and preliminary computational work, and the Einstein Pluripotent Stem Cell Center for their advice and support.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: Dr. Lachman is supported by grants from the National Institute of Mental Health (NIMH) (MH087840 and MH073164). Dr. Zheng is supported by a grant from NIMH(MH087840) and the National Heart, Lung and Blood Institute (NHLBI) (HL104444). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011 10.1038/nature09915. [PMC free article] [PubMed]

2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. 10.1016/j.cell.2007.11.019. [PubMed]

3. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells. 2010 10.1002/stem.499. [PMC free article] [PubMed]

4. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, et al. A model for neural development and treatment of rett syndrome using human induced pluripotent stem cells. Cell. 2010;143(4):527–539. 10.1016/j.cell.2010.10.016. [PMC free article] [PubMed]

5. Marchetto MC, Winner B, Gage FH. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet. 2010;19(R1):R71–6. 10.1093/hmg/ddq159. [PMC free article] [PubMed]

6. Ku S, Soragni E, Campau E, Thomas EA, Altun G, et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell. 2010;7(5):631–637. 10.1016/j.stem.2010.09.014. [PMC free article] [PubMed]

7. Nizzardo M, Simone C, Falcone M, Locatelli F, Riboldi G, et al. Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell Mol Life Sci. 2010;67(22):3837–3847. 10.1007/s00018-010-0463-y. [PubMed]

8. Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009;461(7262):402–406. 10.1038/nature08320. [PMC free article] [PubMed]

9. Chiang CH, Su Y, Wen Z, Yoritomo N, Ross CA, et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry. 2011 10.1038/mp.2011.13. [PubMed]

10. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008;3(3):340–345. 10.1016/j.stem.2008.08.003. [PubMed]

11. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with parkinson's disease. Proc Natl Acad Sci U S A. 2008;105(15):5856–5861. 10.1073/pnas.0801677105. [PubMed]

12. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321(5893):1218–1221. 10.1126/science.1158799. [PubMed]

13. Ginsberg SD, Mirnics K. Functional genomic methodologies. Prog Brain Res. 2006;158:15–40. 10.1016/S0079-6123(06)58002-1. [PubMed]

14. Deep-Soboslay A, Iglesias B, Hyde TM, Bigelow LB, Imamovic V, et al. Evaluation of tissue collection for postmortem studies of bipolar disorder. Bipolar Disord. 2008;10(7):822–828. 10.1111/j.1399-5618.2008.00607.x. [PMC free article] [PubMed]

15. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, et al. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry. 2006;60(6):650–658. 10.1016/j.biopsych.2006.06.019. [PubMed]

16. Hill C, Keks N, Roberts S, Opeskin K, Dean B, et al. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry. 1996;153(4):533–537. [PubMed]

17. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science. 2008;321(5891):956–960. 10.1126/science.1160342. [PubMed]

18. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18(9):1509–1517. 10.1101/gr.079558.108. [PubMed]

19. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat Methods. 2008;5(7):621–628. 10.1038/nmeth.1226. [PubMed]

20. Feng J, Li W, Jiang T. Inference of isoforms from short sequence reads. J Comput Biol. 2011;18(3):305–321. 10.1089/cmb.2010.0243. [PMC free article] [PubMed]

21. Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS. Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci U S A. 2008;105(2):716–721. 10.1073/pnas.0706729105. [PubMed]

22. Mercer TR, Qureshi IA, Gokhan S, Dinger ME, Li G, et al. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 2010;11:14. 10.1186/1471-2202-11-14. [PMC free article] [PubMed]

23. Hattori D, Millard SS, Wojtowicz WM, Zipursky SL. Dscam-mediated cell recognition regulates neural circuit formation. Annu Rev Cell Dev Biol. 2008;24:597–620. 10.1146/annurev.cellbio.24.110707.175250. [PMC free article] [PubMed]

24. O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. Hum Genet. 2009;126(1):3–12. 10.1007/s00439-009-0703-0. [PubMed]

25. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009;164(1):331–343. 10.1016/j.neuroscience.2009.03.080. [PubMed]

26. Williams HJ, Owen MJ, O'Donovan MC. New findings from genetic association studies of schizophrenia. J Hum Genet. 2009;54(1):9–14. 10.1038/jhg.2008.7. [PubMed]

27. Wu JQ, Habegger L, Noisa P, Szekely A, Qiu C, et al. Dynamic transcriptomes during neural differentiation of human embryonic stem cells revealed by short, long, and paired-end sequencing. Proc Natl Acad Sci U S A. 2010;107(11):5254–5259. 10.1073/pnas.0914114107. [PubMed]

28. Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, et al. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood. 2009;113(11):2526–2534. 10.1182/blood-2008-06-162164. [PubMed]

29. Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNA-seq. Bioinformatics. 2009;25(9):1105–1111. 10.1093/bioinformatics/btp120. [PMC free article] [PubMed]

30. Bullard JH, Purdom E, Hansen KD, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-seq experiments. BMC Bioinformatics. 2010;11:94. 10.1186/1471-2105-11-94. [PMC free article] [PubMed]

31. Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature. 2002;420(6915):563–573. 10.1038/nature01266. [PubMed]

32. Wilhelm BT, Marguerat S, Watt S, Schubert F, Wood V, et al. Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature. 2008;453(7199):1239–1243. 10.1038/nature07002. [PubMed]

33. Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL. Genomewide characterization of non-polyadenylated RNAs. Genome Biol. 2011;12(2):R16. 10.1186/gb-2011-12-2-r16. [PMC free article] [PubMed]

34. Khachane AN, Harrison PM. Mining mammalian transcript data for functional long non-coding RNAs. PLoS One. 2010;5(4):e10316. 10.1371/journal.pone.0010316. [PMC free article] [PubMed]

35. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463(7284):1035–1041. 10.1038/nature08797. [PMC free article] [PubMed]

36. Koziol MJ, Garrett N, Gurdon JB. Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr Biol. 2007;17(9):801–807. 10.1016/j.cub.2007.03.062. [PMC free article] [PubMed]

37. Yanagida M, Shimamoto A, Nishikawa K, Furuichi Y, Isobe T, et al. Isolation and proteomic characterization of the major proteins of the nucleolin-binding ribonucleoprotein complexes. Proteomics. 2001;1(11):1390–1404. 2-Z. [PubMed]

38. Johansson H, Svensson F, Runnberg R, Simonsson T, Simonsson S. Phosphorylated nucleolin interacts with translationally controlled tumor protein during mitosis and with Oct4 during interphase in ES cells. PLoS One. 2010;5(10):e13678. 10.1371/journal.pone.0013678. [PMC free article] [PubMed]

39. Alekseev OM, Richardson RT, Tsuruta JK, O'Rand MG. Depletion of the histone chaperone tNASP inhibits proliferation and induces apoptosis in prostate cancer PC-3 cells. Reprod Biol Endocrinol. 2011;9(1):50. 10.1186/1477-7827-9-50. [PMC free article] [PubMed]

40. Eberhart CG, Copeland J, Abel TW. Brief report: S6 ribosomal protein phosphorylation in autistic frontal cortex and cerebellum: A tissue array analysis. J Autism Dev Disord. 2006;36(8):1131–1135. 10.1007/s10803-006-0135-9. [PubMed]

41. Kurotani R, Kumaki N, Naizhen X, Ward JM, Linnoila RI, et al. Secretoglobin 3A2/uteroglobin-related protein 1 is a novel marker for pulmonary carcinoma in mice and humans. Lung Cancer. 2011;71(1):42–48. 10.1016/j.lungcan.2010.04.001. [PMC free article] [PubMed]

42. Ma Z, Swigut T, Valouev A, Rada-Iglesias A, Wysocka J. Sequence-specific regulator Prdm14 safeguards mouse ESCs from entering extraembryonic endoderm fates. Nat Struct Mol Biol. 2011;18(2):120–127. 10.1038/nsmb.2000. [PubMed]

43. Chia NY, Chan YS, Feng B, Lu X, Orlov YL, et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature. 2010;468(7321):316–320. 10.1038/nature09531. [PubMed]

44. Kastler S, Honold L, Luedeke M, Kuefer R, Moller P, et al. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate. 2010;70(6):666–674. 10.1002/pros.21100. [PubMed]

45. Pal P, Xi H, Guha S, Sun G, Helfand BT, et al. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of european ancestry. Prostate. 2009;69(14):1548–1556. 10.1002/pros.20999. [PMC free article] [PubMed]

46. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, et al. Pseudogenes: Pseudo-functional or key regulators in health and disease? RNA. 2011;17(5):792–798. 10.1261/rna.2658311. [PubMed]

47. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 2009;136(6):1017–1031. 10.1016/j.cell.2008.12.044. [PMC free article] [PubMed]

48. Pedrosa E, Shah A, Tenore C, Capogna M, Villa C, et al. Beta-catenin promoter ChIP-chip reveals potential schizophrenia and bipolar disorder gene network. J Neurogenet. 2010 10.3109/01677063.2010.495182. [PubMed]

49. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets. 2006;7(11):1399–1409. [PubMed]

50. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664–1668. [PubMed]

51. van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell. 2010;6(4):369–381. 10.1016/j.stem.2010.02.014. [PMC free article] [PubMed]

52. Singer T, McConnell MJ, Marchetto MC, Coufal NG, Gage FH. LINE-1 retrotransposons: Mediators of somatic variation in neuronal genomes? Trends Neurosci. 2010;33(8):345–354. 10.1016/j.tins.2010.04.001. [PMC free article] [PubMed]

53. Coufal NG, Garcia-Perez JL, Peng GE, Yeo GW, Mu Y, et al. L1 retrotransposition in human neural progenitor cells. Nature. 2009;460(7259):1127–1131. 10.1038/nature08248. [PMC free article] [PubMed]

54. Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ. CART peptides: Regulators of body weight, reward and other functions. Nat Rev Neurosci. 2008;9(10):747–758. 10.1038/nrn2493. [PubMed]

55. Fagergren P, Hurd Y. CART mRNA expression in rat monkey and human brain: Relevance to cocaine abuse. Physiol Behav. 2007;92(1–2):218–225. 10.1016/j.physbeh.2007.05.027. [PubMed]

56. Hunter RG, Bellani R, Bloss E, Costa A, Romeo RD, et al. Regulation of CART mRNA by stress and corticosteroids in the hippocampus and amygdala. Brain Res. 2007;1152:234–240. 10.1016/j.brainres.2007.03.042. [PMC free article] [PubMed]

57. Bartnik M, Chun-Hui Tsai A, Xia Z, Cheung SW, Stankiewicz P. Disruption of the SCN2A and SCN3A genes in a patient with mental retardation, neurobehavioral and psychiatric abnormalities, and a history of infantile seizures. Clin Genet. 2010 10.1111/j.1399-0004.2010.01526.x. [PubMed]

58. Meisler MH, O'Brien JE, Sharkey LM. Sodium channel gene family: Epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010;588(Pt 11):1841–1848. 10.1113/jphysiol.2010.188482. [PubMed]

59. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry. 2003;8(2):186–194. 10.1038/sj.mp.4001241. [PubMed]

60. Tischfield MA, Bosley TM, Salih MA, Alorainy IA, Sener EC, et al. Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development. Nat Genet. 2005;37(10):1035–1037. 10.1038/ng1636. [PubMed]

61. Zollino M, Gurrieri F, Orteschi D, Marangi G, Leuzzi V, et al. Integrated analysis of clinical signs and literature data for the diagnosis and therapy of a previously undescribed 6p21.3 deletion syndrome. Eur J Hum Genet. 2011;19(2):239–242. 10.1038/ejhg.2010.172. [PMC free article] [PubMed]

62. Bosley TM, Salih MA, Alorainy IA, Oystreck DT, Nester M, et al. Clinical characterization of the HOXA1 syndrome BSAS variant. Neurology. 2007;69(12):1245–1253. 10.1212/01.wnl.0000276947.59704.cf. [PMC free article] [PubMed]

63. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. 10.1038/nprot.2008.211. [PubMed]

64. Kim DH, Jeon Y, Anguera MC, Lee JT. X-chromosome epigenetic reprogramming in pluripotent stem cells via noncoding genes. Semin Cell Dev Biol. 2011 10.1016/j.semcdb.2011.02.025. [PMC free article] [PubMed]

65. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311–1323. 10.1016/j.cell.2007.05.022. [PMC free article] [PubMed]

66. Okamoto I, Patrat C, Thepot D, Peynot N, Fauque P, et al. Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development. Nature. 2011 10.1038/nature09872. [PubMed]

67. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature. 2011;472(7341):120–124. 10.1038/nature09819. [PubMed]

68. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008;18(9):1433–1445. 10.1101/gr.078378.108. [PubMed]

69. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. Nat Rev Genet. 2009;10(3):155–159. 10.1038/nrg2521. [PubMed]

70. Mercer TR, Dinger ME, Mariani J, Kosik KS, Mehler MF, et al. Noncoding RNAs in long-term memory formation. Neuroscientist. 2008;14(5):434–445. 10.1177/1073858408319187. [PubMed]

71. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106(28):11667–11672. 10.1073/pnas.0904715106. [PubMed]

72. Ji P, Diederichs S, Wang W, Boing S, Metzger R, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–8041. 10.1038/sj.onc.1206928. [PubMed]

73. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 2010;29(18):3082–3093. 10.1038/emboj.2010.199. [PubMed]

74. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–938. 10.1016/j.molcel.2010.08.011. [PubMed]

75. Ghosh G, Adams JA. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J. 2011;278(4):587–597. 10.1111/j.1742-4658.2010.07992.x; 10.1111/j.1742-4658.2010.07992.x. [PMC free article] [PubMed]

76. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, et al. Towards understanding the schizophrenia code: An expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(2):129–158. 10.1002/ajmg.b.30481. [PubMed]

77. Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, et al. The PVT-1 oncogene is a myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007;213(2):511–518. 10.1002/jcp.21133. [PubMed]

78. Cohen DR, Cheng CW, Cheng SH, Hui CC. Expression of two novel mouse iroquois homeobox genes during neurogenesis. Mech Dev. 2000;91(1–2):317–321. [PubMed]

79. Anselme I, Laclef C, Lanaud M, Ruther U, Schneider-Maunoury S. Defects in brain patterning and head morphogenesis in the mouse mutant fused toes. Dev Biol. 2007;304(1):208–220. 10.1016/j.ydbio.2006.12.025. [PubMed]

80. Bruck T, Benvenisty N. Meta-analysis of the heterogeneity of X chromosome inactivation in human pluripotent stem cells. Stem Cell Res. 2011;6(2):187–193. 10.1016/j.scr.2010.12.001. [PubMed]

81. Marikawa Y, Tamashiro DA, Fujita TC, Alarcon VB. Dual roles of Oct4 in the maintenance of mouse P19 embryonal carcinoma cells: As negative regulator of Wnt/beta-catenin signaling and competence provider for brachyury induction. Stem Cells Dev. 2011;20(4):621–633. 10.1089/scd.2010.0209. [PMC free article] [PubMed]

82. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, et al. Identifying mRNA targets of microRNA dysregulated in cancer: With application to clear cell renal cell carcinoma. BMC Syst Biol. 2010;4:51. 10.1186/1752-0509-4-51. [PMC free article] [PubMed]

83. de la Cruz JM, Bamford RN, Burdine RD, Roessler E, Barkovich AJ, et al. A loss-of-function mutation in the CFC domain of TDGF1 is associated with human forebrain defects. Hum Genet. 2002;110(5):422–428. 10.1007/s00439-002-0709-3. [PubMed]

84. Pedrosa E, Kaushik S, Lachman HM. ChIP-chip analysis of neurexins and other candidate genes for addiction and neuropsychiatric disorders. J Neurogenet. 2010;24(1):5–17. [PubMed]

85. Zheng D, Frankish A, Baertsch R, Kapranov P, Reymond A, et al. Pseudogenes in the ENCODE regions: Consensus annotation, analysis of transcription, and evolution. Genome Res. 2007;17(6):839–851. 10.1101/gr.5586307. [PubMed]

86. Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature. 2008;453(7194):534–538. 10.1038/nature06904. [PMC free article] [PubMed]

87. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465(7301):1033–1038. 10.1038/nature09144. [PMC free article] [PubMed]

88. McCarrey JR, Riggs AD. Determinator-inhibitor pairs as a mechanism for threshold setting in development: A possible function for pseudogenes. Proc Natl Acad Sci U S A. 1986;83(3):679–683. [PubMed]

89. Sun C, Orozco O, Olson DL, Choi E, Garber E, et al. CRIPTO3, a presumed pseudogene, is expressed in cancer. Biochem Biophys Res Commun. 2008;377(1):215–220. 10.1016/j.bbrc.2008.09.113. [PubMed]

90. Hentschke M, Kurth I, Borgmeyer U, Hubner CA. Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3. J Biol Chem. 2006;281(44):33497–33504. 10.1074/jbc.M606975200. [PubMed]

91. Rowen L, Young J, Birditt B, Kaur A, Madan A, et al. Analysis of the human neurexin genes: Alternative splicing and the generation of protein diversity. Genomics. 2002;79(4):587–597. 10.1006/geno.2002.6734. [PubMed]

92. Kang Y, Zhang X, Dobie F, Wu H, Craig AM. Induction of GABAergic postsynaptic differentiation by {alpha}-neurexins. J Biol Chem. 2008;283(4):2323–2334. 10.1074/jbc.M703957200. [PMC free article] [PubMed]

93. Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull. 2009;35(1):96–108. 10.1093/schbul/sbn155. [PMC free article] [PubMed]

94. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E. Genetic Risk and Outcome in Psychosis (GROUP) Consortium. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet. 2008;83(4):504–510. 10.1016/j.ajhg.2008.09.011. [PubMed]

95. Pedrosa E, Ye K, Nolan KA, Morrell L, Okun JM, et al. Positive association of schizophrenia to JARID2 gene. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(1):45–51. 10.1002/ajmg.b.30386. [PubMed]

96. Liu Y, Chen G, Norton N, Liu W, Zhu H, et al. Whole genome association study in a homogenous population in shandong peninsula of china reveals JARID2 as a susceptibility gene for schizophrenia. J Biomed Biotechnol. 2009;2009:536918. 10.1155/2009/536918. [PMC free article] [PubMed]

97. Weiss LA. Autism genetics: Emerging data from genome-wide copy-number and single nucleotide polymorphism scans. Expert Rev Mol Diagn. 2009;9(8):795–803. 10.1586/erm.09.59. [PubMed]

98. Weiss LA, Arking DE, Daly MJ, Chakravarti A. Gene Discovery Project of Johns Hopkins & the Autism Consortium. A genome-wide linkage and association scan reveals novel loci for autism. Nature. 2009;461(7265):802–808. 10.1038/nature08490. [PMC free article] [PubMed]

99. Glaser B, Moskvina V, Kirov G, Murphy KC, Williams H, et al. Analysis of ProDH, COMT and ZDHHC8 risk variants does not support individual or interactive effects on schizophrenia susceptibility. Schizophr Res. 2006;87(1–3):21–27. 10.1016/j.schres.2006.05.024. [PubMed]

100. Glaser B, Kirov G, Bray NJ, Green E, O'Donovan MC, et al. Identification of a potential bipolar risk haplotype in the gene encoding the winged-helix transcription factor RFX4. Mol Psychiatry. 2005;10(10):920–927. 10.1038/sj.mp.4001689. [PubMed]

101. Zhang D, Zeldin DC, Blackshear PJ. Regulatory factor X4 variant 3: A transcription factor involved in brain development and disease. J Neurosci Res. 2007;85(16):3515–3522. 10.1002/jnr.21356. [PMC free article] [PubMed]

102. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis. 2008;30(3):303–311. 10.1016/j.nbd.2008.01.012. [PMC free article] [PubMed]

103. Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet. 2009;5(6):e1000536. 10.1371/journal.pgen.1000536. [PMC free article] [PubMed]

104. Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, et al. CNTNAP2 and NRXN1 are mutated in autosomal-recessive pitt-hopkins-like mental retardation and determine the level of a common synaptic protein in drosophila. Am J Hum Genet. 2009 10.1016/j.ajhg.2009.10.004. [PubMed]

105. Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008;82(1):150–159. 10.1016/j.ajhg.2007.09.005. [PubMed]

106. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2008 10.1093/hmg/ddn351. [PMC free article] [PubMed]

107. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455(7210):232–236. 10.1038/nature07229. [PMC free article] [PubMed]

108. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. Common variants conferring risk of schizophrenia. Nature. 2009 10.1038/nature08186. [PMC free article] [PubMed]

109. O'Dushlaine C, Kenny E, Heron E, Donohoe G, Gill M, et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry. 2010 10.1038/mp.2010.7. [PubMed]

110. Shifman S, Johannesson M, Bronstein M, Chen SX, Collier DA, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008;4(2):e28. 10.1371/journal.pgen.0040028. [PubMed]

111. Lee MT, Chen CH, Lee CS, Chen CC, Chong MY, et al. Genome-wide association study of bipolar I disorder in the han chinese population. Mol Psychiatry. 2010 10.1038/mp.2010.43. [PubMed]

112. Lachman HM, Fann CS, Bartzis M, Evgrafov OV, Rosenthal RN, et al. Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet. 2007;16(11):1327–1334. 10.1093/hmg/ddm081. [PubMed]

113. Chu TT, Liu Y. An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes. J Hum Genet. 2010;55(5):285–292. 10.1038/jhg.2010.24. [PubMed]

114. Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008;82(1):199–207. 10.1016/j.ajhg.2007.09.011. [PubMed]

115. Need AC, Ge D, Weale ME, Maia J, Feng S, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 2009;5(2):e1000373. 10.1371/journal.pgen.1000373. [PMC free article] [PubMed]

116. Arion D, Horvath S, Lewis DA, Mirnics K. Infragranular gene expression disturbances in the prefrontal cortex in schizophrenia: Signature of altered neural development? Neurobiol Dis. 2010;37(3):738–746. 10.1016/j.nbd.2009.12.013. [PMC free article] [PubMed]

117. Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry. 2008 10.1038/mp.2008.33. [PubMed]

118. Sun H, Kawaguchi R. The membrane receptor for plasma retinol-binding protein, a new type of cell-surface receptor. Int Rev Cell Mol Biol. 2011;288:1–41. 10.1016/B978-0-12-386041-5.00001-7. [PubMed]

119. van Neerven S, Kampmann E, Mey J. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases. Prog Neurobiol. 2008;85(4):433–451. 10.1016/j.pneurobio.2008.04.006. [PubMed]

120. Wang KS, Liu XF, Aragam N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr Res. 2010;124(1–3):192–199. 10.1016/j.schres.2010.09.002. [PubMed]

121. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of european ancestry. Proc Natl Acad Sci U S A. 2009;106(18):7501–7506. 10.1073/pnas.0813386106. [PubMed]

122. Purcell SM, Wray NR, Stone JL, Visscher PM, et al. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748–752. 10.1038/nature08185. [PubMed]

123. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40(9):1053–1055. 10.1038/ng.201. [PubMed]

124. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459(7246):528–533. 10.1038/nature07999. [PMC free article] [PubMed]

125. Anney R, Klei L, Pinto D, Regan R, Conroy J, et al. A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet. 2010;19(20):4072–4082. 10.1093/hmg/ddq307. [PMC free article] [PubMed]

126. Magri C, Sacchetti E, Traversa M, Valsecchi P, Gardella R, et al. New copy number variations in schizophrenia. PLoS One. 2010;5(10):e13422. 10.1371/journal.pone.0013422. [PMC free article] [PubMed]

127. Girirajan S, Rosenfeld JA, Cooper GM, Antonacci F, Siswara P, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42(3):203–209. 10.1038/ng.534. [PMC free article] [PubMed]

128. Moreno-De-Luca D, Mulle JG, Kaminsky EB, et al. SGENE ConsortiumSimons Simplex Collection Genetics Consortium. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet. 2010;87(5):618–630. 10.1016/j.ajhg.2010.10.004. [PubMed]

129. Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, et al. Maternally derived microduplications at 15q11–q13: Implication of imprinted genes in psychotic illness. Am J Psychiatry. 2011;168(4):408–417. 10.1176/appi.ajp.2010.09111660. [PMC free article] [PubMed]

130. Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, et al. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry. 2011;16(1):17–25. 10.1038/mp.2009.101. [PMC free article] [PubMed]

131. Ullmann R, Turner G, Kirchhoff M, Chen W, Tonge B, et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum Mutat. 2007;28(7):674–682. 10.1002/humu.20546. [PubMed]

132. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 2009;41(11):1223–1227. 10.1038/ng.474. [PMC free article] [PubMed]

133. Zoltewicz JS, Ashique AM, Choe Y, Lee G, Taylor S, et al. Wnt signaling is regulated by endoplasmic reticulum retention. PLoS One. 2009;4(7):e6191. 10.1371/journal.pone.0006191. [PMC free article] [PubMed]

134. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9(9):1415–1423. [PubMed]

135. Williams JM, Beck TF, Pearson DM, Proud MB, Cheung SW, et al. A 1q42 deletion involving DISC1, DISC2, and TSNAX in an autism spectrum disorder. Am J Med Genet A. 2009;149A(8):1758–1762. 10.1002/ajmg.a.32941. [PMC free article] [PubMed]

136. Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(4):937–947. 10.1002/ajmg.b.31063. [PMC free article] [PubMed]

137. Wilusz JE, Freier SM, Spector DL. 3′ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135(5):919–932. 10.1016/j.cell.2008.10.012. [PMC free article] [PubMed]

138. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: A long non-coding RNA and its important 3′ end functional motif in colorectal cancer metastasis. Int J Oncol. 2011;39(1):169–175. 10.3892/ijo.2011.1007; 10.3892/ijo.2011.1007. [PubMed]

139. Butler JT, Hall LL, Smith KP, Lawrence JB. Changing nuclear landscape and unique PML structures during early epigenetic transitions of human embryonic stem cells. J Cell Biochem. 2009;107(4):609–621. 10.1002/jcb.22183. [PMC free article] [PubMed]

140. Qureshi IA, Mehler MF. Impact of nuclear organization and dynamics on epigenetic regulation in the central nervous system: Implications for neurological disease states. Ann N Y Acad Sci. 2010;1204(Suppl):E20–37. 10.1111/j.1749-6632.2010.05718.x. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of
Public Library of Science